Bristol-Myers Squibb Company (BMY)
| Market Cap | 116.95B +22.3% |
| Revenue (ttm) | 48.48B +1.8% |
| Net Income | 7.28B +34.3% |
| EPS | 3.57 +33.7% |
| Shares Out | 2.04B |
| PE Ratio | 16.04 |
| Forward PE | 9.36 |
| Dividend | $2.52 (4.40%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 9,573,148 |
| Open | 57.03 |
| Previous Close | 56.60 |
| Day's Range | 56.79 - 57.82 |
| 52-Week Range | 42.52 - 62.89 |
| Beta | 0.24 |
| Analysts | Hold |
| Price Target | 63.08 (+10.15%) |
| Earnings Date | Apr 30, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatm... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $63.08, which is an increase of 10.15% from the latest price.
News
Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
Arcus Biosciences (RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY). Under the agreement, Arcus will supply casdatifan, the company’s investigational...
Bristol Myers, SystImmune announce results from analyses of iza-bren studies
SystImmune and Bristol Myers (BMY) Squibb announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical, reported results from prespecified interim analyses of two Phase 3 studies evaluati...
Bristol Myers: Opdivo in combination with AVD receives expanded EU label
Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and adolescent patients 12...
Bristol Myers says FDA accepts sNDA for Camzyos
Bristol Myers (BMY) Squibb announced the U.S. Food and Drug Administration FDA accepted a supplemental New Drug Application for Camzyos as a potential treatment for adolescents with symptomatic obstru...
BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial
BioNTech SE (BNTX) and Bristol Myers Squibb Company (BMY) announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific...
C4 Therapeutics jumps after Bristol Myers myeloma data
Shares of C4 Therapeutics (CCCC) are up 19%, or 70c, to $4.36 in midday trading after Bristol Myers (BMY) announced positive Phase 3 multiple myeloma data.
Bristol Myers says CELMoD mezigdomide reduces risk of disease progression by 52%
Bristol Myers (BMY) Squibb announced late-breaking results from the Phase 3 SUCCESSOR-2 trial of CELMoD mezigdomide in combination with carfilzomib and dexamethasone versus carfilzomib and dexamethaso...
BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees
Bristol Myers Squibb ($BMY), a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with Anthropic to bring its Claude AI model to more…
Bristol Myers announces strategic agreement with Anthropic
Bristol Myers (BMY) Squibb announced a strategic agreement with Anthropic to deploy Claude across the company’s research, clinical development, manufacturing, commercial, and corporate functions. The ...
Bristol-Myers Squibb Company Transcript: Bank of America Global Healthcare Conference 2026
Strong growth in the portfolio is driven by new launches and robust pipeline progress, with double-digit gains in key products and multiple catalysts expected through 2030. Strategic business development and innovation in oncology, neuroscience, and cardiovascular therapies position the company for sustained leadership.
Tempus AI announces strategic collaboration with Bristol Myers
Tempus AI (TEM) announced a new initiative with Bristol Myers Squibb (BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial de...